Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rotigotine
Drug ID BADD_D01973
Description Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Indications and Usage For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
Marketing Status approved
ATC Code N04BC09
DrugBank ID DB05271
KEGG ID D05768
MeSH ID C047508
PubChem ID 59227
TTD Drug ID D81KMY
NDC Product Code 50474-808; 58175-0545; 64552-4020; 43263-0100; 50474-801; 50474-805; 12651-117; 11722-056; 17337-0234; 24196-180; 17337-0033; 65015-815; 50474-802; 64552-4097; 82245-0112; 50474-803; 50474-804; 50474-806; 58032-1022
UNII 87T4T8BO2E
Synonyms rotigotine | 2-(N-n-propyl-N-2-thienylethylamino)-5-hydroxytetralin | N 0437, hydrochloride, (S)-isomer | N 0923 | N-0923 | N 0924 | N-0924 | rotigotine, (+)- | (+)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | Neupro | N 0437 | N-0437 | N 0437, (+-)-isomer | N 0437, (-)-isomer | N 0437, hydrochloride, (R)-isomer | rotigotine, (+--)- | racemic N-0437 | rotigotine (+-)-form | 1-naphthalenol, 5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)- | (+--)-5,6,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | N 0437, (R)-isomer | Rotigotine CDS
Chemical Information
Molecular Formula C19H25NOS
CAS Registry Number 99755-59-6
SMILES CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Libido increased21.03.02.007; 19.08.03.0020.000550%
Liver disorder09.01.08.0010.000367%Not Available
Loss of consciousness17.02.04.0040.002825%Not Available
Lung disorder22.02.07.0010.000367%Not Available
Malaise08.01.01.0030.005797%
Melaena24.07.02.013; 07.12.02.0040.000367%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.003119%
Micturition urgency20.02.02.0060.001651%
Middle insomnia17.15.03.003; 19.02.01.0030.001834%Not Available
Mood swings19.04.03.0010.000367%Not Available
Movement disorder17.01.02.0100.001541%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.001468%Not Available
Muscle spasms15.05.03.0040.002458%
Muscle twitching15.05.03.0050.000367%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.000917%
Musculoskeletal pain15.03.04.007--
Myocardial infarction24.04.04.009; 02.02.02.0070.001101%
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.000550%Not Available
Nervousness19.06.02.0030.000734%Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.0050.001284%Not Available
Nightmare19.02.03.0030.002018%Not Available
Nocturia20.02.03.0010.001834%Not Available
Obsessive-compulsive disorder19.06.05.0020.001357%Not Available
Obsessive-compulsive personality disorder19.05.04.0010.000807%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.002421%
On and off phenomenon17.01.05.0040.003742%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.0200.000367%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages